Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05275972 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Descemet Endothelial Thickness Comparison Trial II

Study acronym: DETECT II
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion moved earlier from Nov 30, 2027 to Oct 30, 2027
    • Study completion moved earlier from Nov 30, 2028 to Oct 30, 2028
    v13
  2. Study sites: 7 to 8
    • Collaborators: 8 to 9
    v12
  3. Primary completion date: Aug 31, 2027 to Nov 30, 2027
    • Study completion date: Aug 31, 2028 to Nov 30, 2028
    • Site contacts updated at 2 of 7 sites
    v11
  4. Site details revised at 4 of 7 sitesv10
  5. Primary completion date: Nov 30, 2026 to Aug 31, 2027v9 Show 4 more changesShow less
    • Study completion date: Nov 30, 2027 to Aug 31, 2028
    • Eligibility criteria shortened, about 42 words
    • Site details revised at 3 of 7 sites
    • Collaborators: 6 to 8
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 4 to 7v8
  2. Primary completion date: Jun 30, 2026 to Nov 30, 2026
    • Study completion date: Jun 30, 2027 to Nov 30, 2027
    v7
  3. Start date changed from estimate of Jan 2023 to Jan 23, 2023v6
  4. Start date: Jul 15, 2022 to Jan 2023
    • Primary completion date: Feb 28, 2026 to Jun 30, 2026
    • Study completion date: Dec 31, 2026 to Jun 30, 2027
    • Eligibility criteria expanded, about 50 words
    v5
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 4
    • Start date changed from estimate of Jul 1, 2022 to Jul 15, 2022
    v4
  6. Primary completion date: Mar 31, 2025 to Feb 28, 2026
    • Start date: May 31, 2022 to Jul 1, 2022
    • Study completion date: Feb 28, 2026 to Dec 31, 2026
    • Collaborators revised (6)
    v3
  7. Start date: Apr 1, 2022 to May 31, 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.
Trial Details
NCT Number NCT05275972
Lead Sponsor Stanford University
Collaborators: Oregon Health and Science University, University of California, San Francisco, University of California, Davis, Case Western Reserve University, Dartmouth-Hitchcock Medical Center, University of Pennsylvania, University of Miami, Wills Eye Hospital, Devers Eye Institute
Conditions
(from sponsor)		 Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
Related terms Fuchs' Endothelial Dystrophy
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov